Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261065 · ClinicalTrials.gov registry record · Phase 4
Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
A Phase 4 study of Heart Failure and Cardiomyopathy, sponsored by Michael E. DeBakey VA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT01261065 is a Phase 4 study of Heart Failure and Cardiomyopathy that has completed, run by Michael E. DeBakey VA Medical Center. The registered enrollment target is 55 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01261065, a Phase 4 study of Heart Failure and Cardiomyopathy, has completed, sponsored by Michael E. DeBakey VA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall hypothesis of this application is that the improvement in LV ejection performance following treatment with betablockers is due, at least in part, to improvement in intrinsic myocardial contractility.
Conditions Studied
Interventions
- DRUG carvedilol
Study Locations (1)
Texas
- Michael E. DeBakey Veterans Affairs Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261065
The ClinicalTrials.gov registry entry for NCT01261065 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Michael E. DeBakey VA Medical Center, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which carvedilol is the first listed.
NCT01261065 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01261065 about?
NCT01261065 is a clinical study titled "Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure". The overall hypothesis of this application is that the improvement in LV ejection performance following treatment with betablockers is due, at least in part, to improvement in intrinsic myocardial contractility.
What is the current status of trial NCT01261065?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2001-12. Estimated completion is 2005-10.
What conditions does trial NCT01261065 study?
This clinical trial studies the following conditions: Heart Failure, Cardiomyopathy.
What interventions are being tested in trial NCT01261065?
The interventions under investigation include: carvedilol (DRUG).
Who is sponsoring clinical trial NCT01261065?
This trial is sponsored by Michael E. DeBakey VA Medical Center, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01261065 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.